De Generic Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 04-12-2024
- Paid Up Capital ₹ 2.50 M
as on 04-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 1.40 Cr
as on 04-12-2024
- Revenue 135.72%
(FY 2014)
- Profit 47.92%
(FY 2014)
- Ebitda -83.33%
(FY 2014)
- Net Worth 33.98%
(FY 2014)
- Total Assets 8.32%
(FY 2014)
About De Generic Bio-Tech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.40 Cr.
Venigalla Srinivas, Sai Akella, and Vijay Pal serve as directors at the Company.
- CIN/LLPIN
U15122TG2011PTC074610
- Company No.
074610
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2011
- Date of AGM
09 Aug 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does De Generic Bio-Tech Private Limited offer?
De Generic Bio-Tech Private Limited offers a wide range of products and services, including Animal Feed Supplement, Aqua Feed Supplement, Fish Foods, Aqua Probiotics, Feed Supplement, Bio Fertilizers, Soil Probiotics and inoculants.
Who are the key members and board of directors at De Generic Bio-Tech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venigalla Srinivas  | Director | 23-May-2011 | Current |
| Sai Akella | Director | 23-May-2011 | Current |
| Vijay Pal | Additional Director | 03-Jul-2018 | Current |
Financial Performance of De Generic Bio-Tech.
De Generic Bio-Tech Private Limited, for the financial year ended 2014, experienced significant growth in revenue, with a 135.72% increase. The company also saw a substantial improvement in profitability, with a 47.92% increase in profit. The company's net worth Soared by an impressive increase of 33.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of De Generic Bio-Tech?
In 2018, De Generic Bio-Tech had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Apr 2016 | ₹1.40 Cr | Open |
How Many Employees Work at De Generic Bio-Tech?
Unlock and access historical data on people associated with De Generic Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of De Generic Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped De Generic Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
